© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Two cases suggest that Viread alone may not be enough to prevent HIV through pre-exposure prophylaxis (PrEP)
Among HIV-positive people, it is preferable to treat hepatitis B with a two-drug regimen rather than with monotherapy.
Viread (tenofovir) is highly effective at suppressing hepatitis B, even after an eight-year period.
Early results of Merck’s combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure ra...
The HIV antiretroviral Viread (tenofovir) is highly effective in combating both HIV and hepatitis B among those coinfected with both viruses
The HIV antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine), can suppress hepatitis B in three-quarters of those with ?immune-toler...
About 12 percent of HIV-positive people with chronic hepatitis B virus (HBV) infection failed to control their HBV after one year with Viread...
The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
